A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: A phase II study

Melanoma Research

Volumn 16, Issue 1, 2006, Pages 65-69

  Ron, Ilan G ^a,b   Sarid, David ^a   Ryvo, Larisa ^a   Even Sapir, Einat ^a   Schneebaum, Shlomo ^a   Metser, Ur ^a   Asna, Noam ^a   Inbar, Moshe J ^a   Safra, Tamar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Biochemotherapy; Interferon alfa 2a (IFN alfa); Interleukin 2 (IL 2); Metastatic malignant melanoma; Temozolomide

Indexed keywords

ALPHA INTERFERON; CISPLATIN; INTERLEUKIN 2; TEMOZOLOMIDE; VINBLASTINE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MALE; MELANOMA; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION; BRAIN TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 33645454090     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000183921.46031.93     Document Type: Article

References (22)

1. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16:34-44.
2. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51:609-630.
3. Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82:1158-1162.
4. McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50:553-556.
5. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
6. Agarwala SS, Kirkwood MJ. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000; 5:144-151.
7. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65:278-291.
8. Gajewski TF. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol 2004; 22:580-581.
9. Legha SS. The role of interferon-alfa in the treatment of metastatic melanoma. Semin Oncol 1997; 24(Suppl 4):S24-S31.
10. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 177:89-96.
11. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13:1110-1122.
12. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, et al. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993; 72:607-614.
13. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
14. World Health Organization. The WHO handbook for reporting results of cancer treatment. WHO Publication no. 48. Geneva: World Health Organization; 1979.
15. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Kian Ang K. Cutaneous melanoma. In: DeVita VJ Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5th edition. Philadelphia, PA: Lippincott-Raven; 1997, pp. 1947-1994.
16. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:1745-1761.
17. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
18. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa 2a for metastatic melanoma. J Clin Oncol 1993; 11:2173-2180.
19. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999; 17:651-657.
20. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine, and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol 1996; 7:827-835.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-975.
22. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15:2579-2588.